chloroquin
weak
base
commonli
use
treatment
malaria
autoimmun
diseas
rheumatoid
arthriti
system
lupu
readili
absorb
administ
either
oral
parenter
becom
highli
concentr
tissu
adren
gland
liver
spleen
tissu
suffer
extens
necrosi
fatal
filovir
cell
tissu
cq
becom
concentr
acid
organel
endosom
lysosom
golgi
therebi
increas
lead
dysfunct
sever
enzym
eg
requir
proteolyt
process
modif
cq
also
inhibit
product
sever
immunolog
mediat
excess
releas
contribut
autoimmun
diseas
system
lupu
erythematosu
rheumatoid
therefor
cq
properti
consid
treatment
filovir
infect
associ
patholog
ph
acid
organel
shown
inhibit
sever
virus
includ
influenza
b
sar
coronaviru
hepat
viru
borna
diseas
viru
requir
low
ph
suggest
cq
could
also
inhibit
filovirus
entri
cytoplasm
suscept
cell
therebi
abrog
infect
sinc
depend
endosom
acidif
activ
sever
host
endosom
proteas
cq
might
also
inhibit
assembl
bud
filovirus
partli
requir
late
endosom
accordingli
dysfunct
enzym
eg
glycosyltransferas
caus
cq
hydroxychloroquin
hcq
direct
result
increas
ph
andor
structur
chang
golgi
apparatu
shown
inhibit
glycosyl
sar
also
therebi
lead
product
noninfecti
virion
viru
decreas
mechan
invok
explain
decreas
viral
load
observ
patient
oral
administ
hcq
mgday
result
though
obtain
nonrel
virus
could
suggest
cq
given
correct
dosag
might
inhibit
glycosyl
ebov
peplom
pronounc
occur
sinc
gp
filovirus
protein
involv
initi
cytotox
depend
inhibit
glycosyl
could
potenti
inhibit
ebov
tropism
broad
varieti
host
cell
organ
lead
product
noninfecti
decreas
infect
viru
seen
decreas
ebov
pathogen
impair
glycosyl
could
therefor
save
time
adapt
immun
respons
normal
fail
fatal
establish
deal
infect
apart
therapeut
exploit
increas
ph
dysfunct
enzym
caus
cq
immunomodulatori
properti
drug
could
also
exploit
therapeut
treatment
filovir
patholog
sever
studi
suggest
multipl
organ
failur
hypovolem
shock
seen
fatal
case
like
result
direct
infect
destruct
suscept
cell
endotheli
cell
effect
cytokin
chemokin
mediat
releas
infect
activ
cell
monocyt
one
cytokin
strongli
implic
patholog
abl
increas
permeabl
endotheli
cell
shown
experi
conduct
human
umbil
also
abl
human
inject
recombin
form
induc
sustain
activ
blood
coagul
also
caus
tissu
injuri
role
patholog
fatal
associ
filovir
infect
confirm
fact
intramuscular
administr
serum
day
postinfect
abl
reduc
circul
concentr
protect
infect
rodent
patient
recov
infect
zair
ebov
zebov
two
recent
outbreak
gabon
transient
increas
plasma
concentr
onset
infect
decreas
cours
infect
convers
fatal
case
display
increas
sustain
concentr
fatal
highli
increas
concentr
solubl
tumour
necrosi
factor
receptor
also
taken
togeth
observ
clearli
show
therapeut
agent
like
cq
abl
prevent
activ
macrophag
also
inhibit
secret
variou
cell
clinic
relev
could
benefit
treatment
filovir
infect
anoth
cytokin
like
implic
ebola
pathogenesi
especi
massiv
apoptosi
lymphopenia
associ
fatal
case
ebov
infect
report
abl
increas
cellular
sensit
apoptosi
upregul
express
fa
fa
fatal
case
ebov
infect
express
fa
fa
ligand
shown
anoth
mechan
might
least
part
account
massiv
apoptosi
detect
filoviru
infect
induct
product
monocytesmacrophag
neopterin
deriv
report
neopterin
induc
apoptosi
rat
alveolar
cell
plasma
concentr
neopterin
significantli
progress
increas
throughout
diseas
cours
fatal
case
zebov
infect
therefor
product
neopterin
upon
stimul
might
also
contribut
massiv
apoptosi
seen
fatal
case
ebov
thu
sinc
massiv
apoptosi
seen
fatal
case
patient
associ
product
neopterin
therapeut
agent
like
cq
shown
clinic
relev
concentr
inhibit
product
neopterin
variou
could
great
benefit
treatment
patient
infect
present
zebov
filovirus
although
mechan
action
cq
variou
vitro
studi
suggest
cq
may
exert
benefit
infect
virus
requir
acid
ph
infect
andor
heavili
glycosyl
evok
detriment
immun
activ
sever
clinic
trial
attempt
use
cq
hcq
prevent
treatment
sever
viral
infect
includ
influenza
b
dengu
viral
infect
report
cq
hcq
either
undetectablemoder
clinic
efficaci
actual
detriment
tabl
possibl
hypothes
mix
disappoint
result
may
attribut
know
thu
achiev
therapeut
steadi
state
plasma
whole
blood
cq
concentr
necessari
exert
therapeut
effect
refer
succeed
text
order
cq
use
treatment
infect
virus
requir
acid
ph
infect
andor
heavili
glycosyl
depend
envelop
glycoprotein
infect
therapeut
steadi
state
plasma
whole
blood
concentr
must
achiev
sustain
patient
viraemia
becom
undetect
succeed
text
summar
evid
use
determin
necessari
therapeut
steadi
state
plasma
whole
blood
cq
concentr
firstli
sever
vitro
studi
shown
optim
uptak
cq
sever
cell
type
isol
differ
anim
rang
concentr
caus
less
secondli
whole
blood
cq
consid
vivo
threshold
cq
toxic
sinc
level
associ
signific
cardiovascular
effect
patient
cq
whilst
patient
concentr
shown
signific
cardiovascular
thirdli
clinic
trial
summar
tabl
trial
administ
highest
hcq
dose
durat
suffici
attain
steadi
state
mean
report
moder
improv
sever
patient
one
highest
hcq
level
approxim
equival
vitro
cq
shown
inhibit
best
respons
hcq
patient
absolut
increas
plasma
level
rna
decreas
cpm
percentag
increas
also
signific
improv
mitogen
although
hiv
depend
acid
organel
infect
less
glycosyl
comparison
hcq
steadi
state
concentr
nevertheless
abl
inhibit
hiv
replic
affect
fourthli
steadi
state
cqhcq
concentr
detect
plasma
whole
blood
respect
shown
vivo
vitro
inhibit
viral
replic
overproduct
immunolog
mediat
associ
patholog
mani
viral
infect
autoimmun
conclud
transient
steadi
state
whole
blood
concentr
cq
like
signific
cardiovascular
steadi
state
whole
blood
concentr
cqhcq
abl
inhibit
viral
replic
glycosyl
product
immunolog
mediat
associ
viral
optim
uptak
cq
human
like
lie
within
rang
therefor
steadi
state
cq
concentr
could
safe
suffici
rais
maintain
acid
organel
ph
level
approxim
neutral
therebi
inhibit
viral
replic
mechan
inhibit
endosom
proteas
inhibit
fusion
viral
membran
host
cell
plasma
membran
inhibit
viral
glycosyl
order
achiev
recommend
therapeut
steadi
state
plasma
whole
blood
cq
concentr
use
slow
continu
constant
iv
infus
could
recommend
sinc
could
effici
achiev
state
therapeut
concentr
control
given
low
cardiovascular
safeti
margin
recommend
use
constant
iv
infus
suggest
precis
dose
infus
rate
filovir
infect
treatment
treatment
malaria
though
seemingli
reason
howev
imposs
stage
primarili
interindividu
differ
pharmacokinet
cq
conclud
steadi
state
cq
concentr
plasma
whole
blood
respect
could
use
treatment
filovir
infect
virus
requir
acid
ph
infect
concentr
need
sustain
patient
viraemia
becom
undetect
state
concentr
howev
rule
efficaci
higher
steadi
state
concentr
though
concentr
might
accompani
sever
advers
effect
toxic
subsequ
research
support
conclus
preced
text
confirm
deriv
cq
protect
effect
ebola
infect
author
declar
conflict
interest
